5. FEJEZET | HIVATKOZÁSOK

  1. Di Minno G, Navarro D, Perno CF, et al. Pathogen reduction/inac- tivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients? Ann Hematol. 2017;96(8):1253-1270.
  2. Farrugia A. Guide for the Assessment of Clotting Factor Concentrates, 3rd ed. Montreal, Canada: World Federation of Hemophilia; 2017. https://www1.wfh.org/publication/files/pdf-1271.pdf. Hozzáférés: 2019. szeptember 25.
  3. World Federation of Hemophilia. Online Registry of Clotting Factor Concentrates. World Federation of Hemophilia website. Montreal, Canada: World Federation of Hemophilia; 2020. https://www1. wfh.org/custom/CFC/index.html. Hozzáférés: 2019. szeptember 25.
  4. 6 factor VIII concentrates, factor VIII/von Willebrand factor concentrates, factor IX concentrates, activated prothrombin complex concentrates. Transfus Med Hemother. 2009;36(6):409-418.
  5. Franchini M, Makris M, Santagostino E, Coppola A, Mannucci PM. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand’ s disease: a systematic review of prospective studies. Haemophilia. 2012;18(3):e164-e172.
  6. Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia. 2011;17(3):494-499.
  7. Castaman G, Goodeve A, Eikenboom J, European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. H aematologica. 2013;98(5):667-674.
  8. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370(9585):439-448.
  9. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care. 2011;15(1):201.
  10. Klamroth R, Groner A, Simon TL. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates. Transfusion. 2014;54(5):1406-1417.
  11. Farrugia A, Liumbruno GM, Candura F, Profili S, Cassar J. Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia. Blood Transfus. 2018;16(6):525-534.
  12. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40(11):815-832.
  13. Tiede A, Cid AR, Goldmann G, et al. Body mass index best predicts recovery of recombinant factor VIII in underweight to obese patients with severe haemophilia A. Thromb Haemost. 2020;120(2):277-288.
  14. Hemophilia of Georgia. Protocols for the Treatment of Hemophilia and von Willebrand Disease. Hemophilia of Georgia website. Sandy Springs, GA: Hemophilia of Georgia. https://www.hog.org/publications/page/protocols-for-the-treatment-of-hemophilia-and-von- willebrand-disease-2. Hozzáférés: 2019. szeptember 25.
  15. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost. 2017;15(12):2461-2465.
  16. Martinowitz U, Luboshitz J, Bashari D, et al. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia. 2009;15(3):676-685.
  17. Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol. 1992;82(4):729-734.
  18. Mathews V, Viswabandya A, Baidya S, et al. Surgery for hemophilia in developing countries. Semin Thromb Hemost. 2005;31(5):538-543.
  19. von Auer C, Oldenburg J, von Depka M, et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci. 2005;1051:498-505.
  20. Batorova A, Holme P, Gringeri A, et al. Continuous infusion in haemophilia: current practice in Europe. Haemophilia. 2012;18(5):753-759.
  21. Batorova A, Martinowitz U. Continuous infusion of coagulation products in hemophilia. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia, 3rd ed. Hoboken, NJ: Wiley-Blackwell; 2014:204-212.
  22. A lamelu J, Bevan D, Sorensen B, Rangarajan S. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study. J Thromb Haemost. 2014;12(12):2044-2048.
  23. Ragni MV. New and emerging agents for the treatment of hemophilia: focus on extended half-life recombinant clotting proteins. Drugs. 2015;75(14):1587-1600.
  24. Curtis R, Baker J, Riske B, et al. Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status. Am J Hematol. 2015;90(Suppl 2):S11-S16.
  25. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038-2044.
  26. Peters R, Harris T. Advances and innovations in haemophilia treatment. Nat Rev Drug Discov. 2018;17(7):493-508.
  27. Baldo BA. Chimeric fusion proteins used for therapy: indications, mechanisms, and safety. DrugSaf. 2015;38(5):455-479.
  28. Lubich C, Allacher P, de la Rosa M, et al. The mystery of antibodies against polyethylene glycol (PEG)–what do we know? Pharm Res. 2016;33(9):2239-2249.
  29. Collins P, Chalmers E, Chowdary P, et al. The use of enhanced halflife coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22(4):487-498.
  30. Iorio A, Fischer K, Blanchette V, et al. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost. 2017;117(6):1023-1030.
  31. Cooley B, Broze GJ Jr, Mann DM, Lin FC, Pedersen LG, Stafford DW. Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model. Blood. 2019;133(22):2445-2451.
  32. Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E. Defining extended half-life rFVIII–a critical review of the evidence. Haemophilia. 2018;24(3):348-358.
  33. Ragni MV, Croteau SE, Morfini M, et al. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(7):1437-1441.
  34. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935-1939.
  35. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia. 2006;12(Suppl 6):48-52; discussion.
  36. Giansily-Blaizot M, Schved JF. Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date. Ther Adv Hematol. 2017;8(12):345-352.
  37. N ovoSeven® RT (coagulation factor VIIa, recombinant) lyophilized powder for solution, for intravenous use [U.S. prescribing information]. Plainsboro, NJ: Novo Nordisk; Revised 01/2019.
  38. Negrier C, Voisin S, Baghaei F, et al. Global post-authorization safety surveillance study: real-world data on prophylaxis and on- demand treatment using FEIBA (an activated prothrombin complex concentrate). Blood Coagul Fibrinolysis. 2016;27(5):551-556.
  39. FEIBA (anti-inhibitor coagulant complex) for intravenous use, lyophilized powder for solution [U.S. prescribing information]. Lexington, MA: Baxalta US; Revised 02/2020.
  40. Varadi K, Tangada S, Loeschberger M, et al. Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy. Haemophilia. 2016;22(4):615-624.
  41. Kasper CK. Products for clotting factor replacement in developing countries. Semin Thromb Hemost. 2005;31(5):507-512.
  42. Chamberland ME. Surveillance for transfusion-transmitted viral infections in the United States. Biologicals. 1998;26(2):85-88.
  43. Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology Am Soc Hematol Educ Program. 2007;179-186.
  44. Budde U, Drewke E. Von Willebrand factor multimers in virus- inactivated plasmas and FVIII concentrates. Beitr Infusionsther Transfusionsmed. 1994;32:408-414.
  45. Chin S, Williams B, Gottlieb P, et al. Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants. Blood. 1995;86(11):4331-4336.
  46. Chuansumrit A, Isarangkura P, Chantanakajornfung A, et al. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. J Med Assoc Thai. 1999;82(Suppl 1):S69-S73.
  47. El-Ekiaby M, Sayed MA, Caron C, et al. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med. 2010;20(1):48-61.
  48. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90(7):2515-2521.
  49. Franchini M, Rossetti G, Tagliaferri A, et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia. 2005;11(5):504-509.
  50. van Velzen AS, Eckhardt CL, Peters M, et al. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study. J Thromb Haemost. 2017;15(7):1422-1429.
  51. Loomans JI, Kruip M, Carcao M, et al. Desmopressin in moderate hemophilia A patients: a treatment worth considering. Haematologica. 2018;103(3):550-557.
  52. Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001;7(3):258-266.
  53. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood. 2005;105(8):3382.
  54. Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia. 2012;18(1):25-33.
  55. Castaman G. Desmopressin for the treatment of haemophilia. Haemophilia. 2008;14(Suppl 1):15-20.
  56. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol. 1992;82(1):87-93.
  57. Khair K, Baker K, Mathias M, Burgess C, Liesner R. Intranasal desmopressin (Octim): a safe and efficacious treatment option for children with bleeding disorders. Haemophilia. 2007;13(5):548-551.
  58. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. A nn Intern Med. 1991;114(7):563-568.
  59. Ozgonenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J. 2007;83(977):159-163.
  60. Sica DA, Gehr TW. Desmopressin: safety considerations in patients with chronic renal disease. Drug Saf. 2006;29(7):553-556.
  61. Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. J Pediatr Hematol Oncol. 2005;27(6):330-332.
  62. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. A m J Hematol. 1989;31(3):199-202.
  63. Stoof SC, Cnossen MH, de Maat MP, Leebeek FW, Kruip MJ. Side effects of desmopressin in patients with bleeding disorders. Haemophilia. 2016;22(1):39-45.
  64. Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia. 2014;20(2):158-167.
  65. Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339(4):245-253.
  66. Coetzee MJ. The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia. Haemophilia. 2007;13(4):443-444.
  67. Frachon X, Pommereuil M, Berthier AM, et al. Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000- 2002). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99(3):270-275.
  68. Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009;145(2):212-220.
  69. Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis. 2010;21(7):615-619.
  70. Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost. 2007;5(12):2408-2414.
  71. Tran HT, Sorensen B, Rea CJ, et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia. 2014;20(3):369-375.
  72. Holmstrom M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A–a two- centre experience. Haemophilia. 2012;18(4):544-549.
  73. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia. 2004;10(Suppl 2):10-16.
  74. Franchini M, Marano G, Pati I, et al. Emicizumab for the treatment of haemophilia A: a narrative review. Blood Transfus. 2019;17(3):223-228.
  75. HEMLIBRA® (emicizumab-kxwh) injection for subcutaneous use [U.S. prescribing information]. South San Francisco, CA: Genentech; Revised 10/2018.
  76. European Medicines Agency. European public assessment report: summary of risk management plan for Hemlibra (emicizumab). Updated April 12, 2019. http://www.ema.europa.eu/en/documents/rmp-summary/hemlibra-epar-risk-management-plan-summary_
    en.pdf. Hozzáférés: 2020. február 13.
  77. Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377(9):819-828.
  78. Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of con- cizumab in people with hemophilia A. J Thromb Haemost. 2018;16(11):2184-2195.

TOVÁBBI INFORMÁCIÓ

További kiegészítő információk találhatóak online a További információk részben.6. fejezet: Profi- laxis a hemofíliában